TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy
Brief Summary: The study aims at comparing the safety, tolerability and efficacy of Mefloquine (MQ) to Sulfadoxine-Pyrimethamine (SP) as Interment Preventive Treatment in pregnancy (IPTp) for the prevention of malaria effects on the mother and her infant.


Options:
A: Arm Label: DHAPQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Arm Label: MQAS; Type: EXPERIMENTAL; Interventions: Drug: Artesunate-mefloquine | Arm Label: AQAS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine | Arm Label: AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): DHAPQ | Intervention Type: DRUG; Name: Artesunate-mefloquine; Assigned to Arm(s): MQAS | Intervention Type: DRUG; Name: Artesunate-amodiaquine; Assigned to Arm(s): AQAS | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): AL
B: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A
C: Arm Label: Trial 1: IPTp-SP+LLITNs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine | Arm Label: Trial 1: IPTp-MQ (full dose) + LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (full dose) | Arm Label: Trial 1: IPTp-MQ (split dose)+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (split dose) | Arm Label: Trial 2: CTX+IPTp-Placebo+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Trial 2: CTX + IPTp-MQ+ LLITNs; Type: EXPERIMENTAL; Interventions: Drug: mefloquine | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): Trial 1: IPTp-SP+LLITNs | Intervention Type: DRUG; Name: Mefloquine (full dose); Assigned to Arm(s): Trial 1: IPTp-MQ (full dose) + LLITNs | Intervention Type: DRUG; Name: Mefloquine (split dose); Assigned to Arm(s): Trial 1: IPTp-MQ (split dose)+LLITNs | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Trial 2: CTX+IPTp-Placebo+LLITNs | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Trial 2: CTX + IPTp-MQ+ LLITNs
D: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy
Brief Summary: The study aims at comparing the safety, tolerability and efficacy of Mefloquine (MQ) to Sulfadoxine-Pyrimethamine (SP) as Interment Preventive Treatment in pregnancy (IPTp) for the prevention of malaria effects on the mother and her infant.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A
C: Arm Label: DHAPQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Arm Label: MQAS; Type: EXPERIMENTAL; Interventions: Drug: Artesunate-mefloquine | Arm Label: AQAS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine | Arm Label: AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): DHAPQ | Intervention Type: DRUG; Name: Artesunate-mefloquine; Assigned to Arm(s): MQAS | Intervention Type: DRUG; Name: Artesunate-amodiaquine; Assigned to Arm(s): AQAS | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): AL
D: Arm Label: Trial 1: IPTp-SP+LLITNs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine | Arm Label: Trial 1: IPTp-MQ (full dose) + LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (full dose) | Arm Label: Trial 1: IPTp-MQ (split dose)+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (split dose) | Arm Label: Trial 2: CTX+IPTp-Placebo+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Trial 2: CTX + IPTp-MQ+ LLITNs; Type: EXPERIMENTAL; Interventions: Drug: mefloquine | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): Trial 1: IPTp-SP+LLITNs | Intervention Type: DRUG; Name: Mefloquine (full dose); Assigned to Arm(s): Trial 1: IPTp-MQ (full dose) + LLITNs | Intervention Type: DRUG; Name: Mefloquine (split dose); Assigned to Arm(s): Trial 1: IPTp-MQ (split dose)+LLITNs | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Trial 2: CTX+IPTp-Placebo+LLITNs | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Trial 2: CTX + IPTp-MQ+ LLITNs

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week, Multi-center, Double-blind, Randomized, Placebo-controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2
Brief Summary: This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.


Options:
A: Arm Label: Furosemide first, then Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Furosemide first, then Acetazolamide | Arm Label: Acetazolamide first, then Furosemide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide first, then Furosemide | Intervention Type: DRUG; Name: Furosemide first, then Acetazolamide; Assigned to Arm(s): Furosemide first, then Acetazolamide | Intervention Type: DRUG; Name: Acetazolamide first, then Furosemide; Assigned to Arm(s): Acetazolamide first, then Furosemide
B: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: weight reduction; Type: EXPERIMENTAL; Interventions: Behavioral: weight reduction | Intervention Type: BEHAVIORAL; Name: weight reduction; Assigned to Arm(s): weight reduction
C: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bardoxolone Methyl (RTA 402): 75mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Arm Label: Bardoxolone Methyl (RTA 402): 150mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Arm Label: Bardoxolone Methyl (RTA 402): 25mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bardoxolone Methyl (RTA 402); Assigned to Arm(s): Bardoxolone Methyl (RTA 402): 150mg, Bardoxolone Methyl (RTA 402): 25mg, Bardoxolone Methyl (RTA 402): 75mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open, Single Center, Randomised, Parallel Group Pilot Study to Investigate a Calcineurin Free Immunosuppressive Treatment for de Novo Renal Transplant Recipients: A Comparison of a Rapamycin/MMF/Steroids Regime to a Cyclosporine A Neoral/MMF/Steroids Regimen in the Prevention of Acute Rejection Following Renal Transplantation
Brief Summary: The main purpose of this study is to obtain preliminary information on the efficacy, safety and cost of two regimens, Rapamycin / MMF / steroid therapy and Cyclosporine A Neoral / MMF / steroid therapy, used in the prevention of acute rejection following renal transplantation.


Options:
A: Arm Label: Calcineurin free; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus, Drug: Prednisone, Drug: Mycophenolate mofetil, Procedure: Protocol biopsies | Arm Label: Calcineurin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine A, Drug: Prednisone, Drug: Mycophenolate mofetil, Procedure: Protocol biopsies | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): Calcineurin free | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Calcineurin | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Calcineurin, Calcineurin free | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Calcineurin, Calcineurin free | Intervention Type: PROCEDURE; Name: Protocol biopsies; Assigned to Arm(s): Calcineurin, Calcineurin free
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus/Sirolimus | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus/MMF | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Neoral/Sirolimus | Intervention Type: DRUG; Name: Tacrolimus/Sirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Tacrolimus/MMF; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Neoral/Sirolimus; Assigned to Arm(s): C
C: Arm Label: Low-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: High-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolic Acid (MPA), Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Mycophenolic Acid (MPA); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Cyclosporine A (CsA); Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group
D: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open, Single Center, Randomised, Parallel Group Pilot Study to Investigate a Calcineurin Free Immunosuppressive Treatment for de Novo Renal Transplant Recipients: A Comparison of a Rapamycin/MMF/Steroids Regime to a Cyclosporine A Neoral/MMF/Steroids Regimen in the Prevention of Acute Rejection Following Renal Transplantation
Brief Summary: The main purpose of this study is to obtain preliminary information on the efficacy, safety and cost of two regimens, Rapamycin / MMF / steroid therapy and Cyclosporine A Neoral / MMF / steroid therapy, used in the prevention of acute rejection following renal transplantation.


Options:
A: Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cyclosporine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Mycophenolate mofetil withdrawal; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cyclosporione A withdrawal; Assigned to Arm(s): N/A
C: Arm Label: Calcineurin free; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus, Drug: Prednisone, Drug: Mycophenolate mofetil, Procedure: Protocol biopsies | Arm Label: Calcineurin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine A, Drug: Prednisone, Drug: Mycophenolate mofetil, Procedure: Protocol biopsies | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): Calcineurin free | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Calcineurin | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Calcineurin, Calcineurin free | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Calcineurin, Calcineurin free | Intervention Type: PROCEDURE; Name: Protocol biopsies; Assigned to Arm(s): Calcineurin, Calcineurin free
D: Arm Label: CNI standard regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Myfortic, Drug: Sandimmun Optoral, Drug: Simulect® | Arm Label: CNI free regimen; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Myfortic, Drug: Sandimmun Optoral | Arm Label: CNI low regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus, Drug: Sandimmun Optoral | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): CNI free regimen, CNI low regimen | Intervention Type: DRUG; Name: Myfortic; Assigned to Arm(s): CNI free regimen, CNI standard regimen | Intervention Type: DRUG; Name: Sandimmun Optoral; Assigned to Arm(s): CNI free regimen, CNI low regimen, CNI standard regimen | Intervention Type: DRUG; Name: Simulect®; Assigned to Arm(s): CNI standard regimen

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Continuous Positive Airway Pressure in Patients With Resistant Hypertension and Obstructive Sleep Apnea
Brief Summary: Obstructive sleep apnea (OSA) is an important cause of refractory hypertension but the impact of treatment with continuous positive airway pressure (CPAP) is not completely understood. The aim of this project is to study the effects of CPAP on blood pressure control and its influences on cardiac remodeling and arterial stiffness in patients with refractory hypertension and moderate or severe OSA.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): 2
B: Arm Label: CPAP; Type: EXPERIMENTAL; Interventions: Device: CPAP, Other: Standard care for OSA | Arm Label: Standard care for OSA; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care for OSA | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP | Intervention Type: OTHER; Name: Standard care for OSA; Assigned to Arm(s): CPAP, Standard care for OSA
C: Intervention Type: DEVICE; Name: CPAP (Continuous Positive Airway Pressure); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of ABT-143 to Simvastatin in Subjects With Hypercholesterolemia
Brief Summary: The primary purpose of this study is to test the effect and safety of three different doses of ABT-143 compared to simvastatin in subjects with elevated levels of low density lipoprotein cholesterol ("bad cholesterol") and triglycerides.


Options:
A: Intervention Type: DRUG; Name: rosuvastatin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 3
C: Arm Label: A - ABT-143 capsules 5/135 mg; Type: EXPERIMENTAL; Interventions: Drug: ABT-143 | Arm Label: B - ABT-143 capsules 10/135 mg; Type: EXPERIMENTAL; Interventions: Drug: ABT-143 | Arm Label: C - ABT-143 capsules 20/135 mg; Type: EXPERIMENTAL; Interventions: Drug: ABT-143 | Arm Label: D - Simvastatin capsules 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Intervention Type: DRUG; Name: ABT-143; Assigned to Arm(s): A - ABT-143 capsules 5/135 mg, B - ABT-143 capsules 10/135 mg, C - ABT-143 capsules 20/135 mg | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): D - Simvastatin capsules 40 mg
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Brief Summary: The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: S-1 + irinotecan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: irinotecan | Intervention Type: DRUG; Name: S-1 + irinotecan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): B
B: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla
C: Arm Label: 1. PEP02; Type: EXPERIMENTAL; Interventions: Drug: PEP02 | Arm Label: 2. irinotecan; Type: ACTIVE_COMPARATOR; Interventions: Drug: irinotecan | Arm Label: 3. docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: docetaxel | Intervention Type: DRUG; Name: PEP02; Assigned to Arm(s): 1. PEP02 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 2. irinotecan | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): 3. docetaxel
D: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Electronic Integration of Care for Better Diabetes Outcomes; The COMPETE II Study
Brief Summary: This study will evaluate whether the use of an electronic diabetes tracker by both patients and family physicians in Ontario improves diabetes outcomes, satisfaction with care and with technology and health data privacy issues. As part of the study, the investigators will be able to test whether practices that use computers perform any better than practices using paper. The investigators also will be developing the first Canadian computerized chart summary for each patient that can be communicated securely in emergencies (the Emergency Health Record) and read by all current electronic systems.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: mobile application for diabetes | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: mobile application for diabetes; Assigned to Arm(s): Intervention
B: Arm Label: Electronic disease management decision support; Type: OTHER; Interventions: Other: Electronic disease management decision support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic disease management decision support; Assigned to Arm(s): Electronic disease management decision support
C: Arm Label: Pharmacist management; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical pharmacist-based intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical pharmacist-based intervention; Assigned to Arm(s): Pharmacist management
D: Arm Label: Training course for practice nurses in autonomy support; Type: EXPERIMENTAL; Interventions: Behavioral: Training course for practice nurses in autonomy support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training course for practice nurses in autonomy support; Assigned to Arm(s): Training course for practice nurses in autonomy support

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Electronic Integration of Care for Better Diabetes Outcomes; The COMPETE II Study
Brief Summary: This study will evaluate whether the use of an electronic diabetes tracker by both patients and family physicians in Ontario improves diabetes outcomes, satisfaction with care and with technology and health data privacy issues. As part of the study, the investigators will be able to test whether practices that use computers perform any better than practices using paper. The investigators also will be developing the first Canadian computerized chart summary for each patient that can be communicated securely in emergencies (the Emergency Health Record) and read by all current electronic systems.


Options:
A: Arm Label: ATSM Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM Intervention | Arm Label: GMV Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GMV Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ATSM Intervention; Assigned to Arm(s): ATSM Intervention | Intervention Type: BEHAVIORAL; Name: GMV Intervention; Assigned to Arm(s): GMV Intervention
B: Arm Label: Electronic disease management decision support; Type: OTHER; Interventions: Other: Electronic disease management decision support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic disease management decision support; Assigned to Arm(s): Electronic disease management decision support
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group
D: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A

Answer: B